




Coding with MedDRA



MedDRA was developed under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The activities of the MedDRA Maintenance and Support Services Organization (MSSO) are overseen by an ICH MedDRA Management Committee, which is composed of the ICH parties, the Medicines and Healthcare products Regulatory Agency (MHRA) of the UK, Health Canada, and the WHO (as Observer).



000681

2



MedDRA

Disclaimer & Copyright Notice

- This presentation is protected by copyright and may, with the exception of the MedDRA and ICH logos, be used, reproduced, incorporated into other works, adapted, modified, translated or distributed under a public license provided that ICH's copyright in the presentation is acknowledged at all times. In case of any adaption, modification or translation of the presentation, reasonable steps must be taken to clearly label, demarcate or otherwise identify that changes were made to or based on the original presentation. Any impression that the adaption, modification or translation of the original presentation is endorsed or sponsored by the ICH must be avoided.
- The presentation is provided "as is" without warranty of any kind. In no event shall the ICH or the authors of the original presentation be liable for any claim, damages or other liability arising from the use of the presentation.
- The above-mentioned permissions do not apply to content supplied by third parties. Therefore, for documents where the copyright vests in a third party, permission for reproduction must be obtained from this copyright holder.

000681

3



MedDRA

Course Overview

- Describe MedDRA's background, scope, structure, and characteristics (including primary SOC allocation rules)
- Discuss the maintenance of MedDRA, coding conventions, synonym lists, and coding quality assurance
- Introduce the MedDRA Term Selection: Points to Consider document
- Discuss and present examples of coding exercises with MedDRA

000681

4




MedDRA Background

000681

5

The slide features a white background with a blue and green MedDRA logo in the top left. A vertical line separates the logo from the title. The title 'MedDRA Background' is centered in a green font. In the bottom right, there is a decorative graphic of several green, rounded rectangular shapes of varying heights, and a small blue square containing the number '5'. A small ID number '000681' is in the bottom left.



What is MedDRA?

Med = Medical
D = Dictionary for
R = Regulatory
A = Activities

000681

6

The slide features a white background with a blue and green MedDRA logo in the top left. A vertical line separates the logo from the title. The title 'What is MedDRA?' is centered in a blue font. Below the title, the acronym is broken down into its components: 'Med = Medical', 'D = Dictionary for', 'R = Regulatory', and 'A = Activities'. At the bottom, there is a blurred image of a person's hand holding a clipboard. A small ID number '000681' is in the bottom left, and a small blue square containing the number '6' is in the bottom right.



MedDRA

MedDRA Definition

MedDRA is a clinically-validated international medical terminology used by regulatory authorities and the regulated biopharmaceutical industry. The terminology is used through the entire regulatory process, from pre-marketing to post-marketing, and for data entry, retrieval, evaluation, and presentation.

000681

7




MedDRA

MedDRA's Purpose


- Facilitate the exchange of clinical information through **standardization**
- Important tool for product evaluation, monitoring, communication, electronic records exchange, and oversight
- Supports coding (data entry) and retrieval and analysis of clinical information about human medical products including pharmaceuticals, biologics, vaccines, and drug-device combination products

000681


8




MedDRA and the MSSO




MSSO
International support and development of terminology
"Custodians", not owners, of the terminology



Governance
Governed by a Management Committee (industry, regulators,
multi-national, other interested parties)




Educational offerings
Foster use of MedDRA through communications and
educational offerings




JMO
Partner organization for Japanese-language MedDRA

000681

9



Where MedDRA is Used





MedDRA


- Regulatory Authority and Industry Databases
- Individual Case Safety Reports and Safety Summaries
- Clinical Study Reports
- Investigators' Brochures
- Core Company Safety Information
- Marketing Applications
- Publications
- Prescribing Information
- Advertising




000681

10






MedDRA Data Sharing




Access

Subscription grants access to MedDRA for one year




3rd Party Distribution

Subscriber cannot grant any sublicense, publish or otherwise distribute MedDRA to a third party



Free Exchange


Data may be freely exchanged between current MedDRA subscribers



Violation


Sharing MedDRA with a non-subscribing organization is a violation of the MedDRA license

000681 13




MedDRA Data Sharing (cont)

- For details, see the Statement on MedDRA Data Sharing




000681 14



MedDRA's Scope, Structure, and Characteristics

000681 15



Scope of MedDRA

Not a drug dictionary

Patient demographic terms

Clinical trial study design terms

OUT

IN

Medical conditions

Indications

Investigations (tests, results)

Medical and surgical procedures

Medical, social, family history

Medication errors

Product quality issues

Device-related issues

Product use issues

Pharmacogenetic terms

Toxicologic issues

Standardized queries



Frequency qualifiers


Numerical values for results

Severity descriptors

Not an equipment, device, diagnostic product dictionary

000681 16





MedDRA Non-Current Terms LLT

- Flagged at the LLT level in MedDRA
- Not recommended for continued use
- Retained to preserve historical data for retrieval and analysis
- Terms that are vague, ambiguous, outdated, truncated, or misspelled
- Terms derived from other terminologies that do not fit MedDRA rules

000681 20



MedDRA

MedDRA Codes

PT Anaemia

[10002034]

- Each MedDRA term is assigned an 8-digit numeric code
 - Non-expressive
 - Assigned sequentially
- Codes can fulfill a data field in various electronic submission types (e.g., E2B)

000681

21



MedDRA

Current and Planned MedDRA Translations



000681

22



MedDRA

A Multi-Axial Terminology

Multi-axial = the representation of a medical concept in multiple SOC

- ✓ Allows grouping by different classifications
- ✓ Allows retrieval and presentation via different data sets

All PTs assigned a primary SOC

- ✓ Determines which SOC will represent a PT during cumulative data outputs
- ✓ Prevents "double counting"
- ✓ Supports standardized data presentation
- ✓ Pre-defined allocations should not be changed by users

000681

23



MedDRA

A Multi-Axial Terminology (cont)

SOC = Respiratory, thoracic and mediastinal disorders
(Secondary SOC)

SOC = Infections and infestations
(Primary SOC)

HLGT = Respiratory tract infections

HLGT = Viral infectious disorders


HLT = Viral upper respiratory tract infections

HLT = Influenza viral infections

PT = Influenza

000681


24



Rules for Primary SOC Allocation (cont.)




- PTs represented in only one SOC are automatically assigned that SOC as primary
- PTs for diseases, signs and symptoms are assigned to prime manifestation site SOC
- Congenital and hereditary anomalies terms have SOC *Congenital, familial and genetic disorders* as Primary SOC
- Neoplasms terms have SOC *Neoplasms benign, malignant and unspecified (incl cysts and polyps)* as Primary SOC
 - **Exception:** Cysts and polyps have prime manifestation site SOC as Primary SOC
- Infections and infestations terms have SOC *Infections and infestations* as Primary SOC

000681 25



Primary SOC Priority

If a PT links to more than one of the exceptions, the following priority will be used to determine primary SOC:

-  *Congenital, familial and genetic disorders*
-  *Neoplasms benign, malignant and unspecified (incl cysts and polyps)*
-  *Infections and infestations*

000681 26



MedDRA

A Multi-Axial Terminology (cont)

PTs in the following SOC **only** appear in that particular SOC and not in others, i.e., they are not multi-axial

- *Investigations*
- *Surgical and medical procedures*
- *Social circumstances*

000681

27



MedDRA

Can You Select the Primary SOC for This PT?

PT	HLT	HLGT	SOC
Congenital HIV infection	Viral infections congenital	Infections and infestations congenital	Congenital, familial and genetic disorders
	Congenital neonatal infections	Neonatal and perinatal conditions	Pregnancy, puerperium and perinatal conditions
	Retroviral infections	Viral infectious disorders	Infections and infestations
	Acquired immunodeficiency syndromes	Immunodeficiency syndromes	Immune system disorders

000681


28



MedDRA Maintenance

000681

29




MedDRA Maintenance

- Users can send change requests (CRs) to MSSO for consideration
 - Organizations allowed 100 CRs/month
 - Rigorous medical review by MSSO physicians
 - For simple changes (PT and LLT levels), response within 7-10 working days
 - Complex changes (above PT level) posted for comments mid-year
- Two MedDRA updates/year
 - 1 March X.0 (Complex release)
 - 1 September X.1 (Simple release)


000681


30



- Web-based tool for Change Requests (CR)
 - URL: <https://mssotools.com/webcr/>
 - Via the Change Request Information page
- Ability to submit CRs online
 - Requests must be in English
- Immediate confirmation
- Review unsubmitted CRs online
- Ability to query CR history back to v5.1

000681 31





Freeze Date for MedDRA Version 25.1
1 June 2022 17:00 U.S. EDT
[MedDRA Documentation](#)
[MedDRA Privacy Statement](#)

Login to WebCR


MedDRA ID:

Password:

Welcome to the MedDRA User Change Request Data Entry Web site.
You may submit your MedDRA Change Request to the MSSO here.
If you have problems logging in, please contact the MSSO Help Desk at:
MSSOHelp@meddra.org or 1-877-268-8280


- Online change request submission tool guides user to enter all needed information
- Instructional video on use of WebCR on “Training” page of MedDRA website

000681 32



Submitting Changes (cont)

Add a New PT

Proposed PT (Required) 

Second degree chemical burns of skin

Primary HLT (Optional)

Chemical injuries

Primary SOC (Optional)

Injury, poisoning and procedural complications


Secondary HLT (Optional)

Dermatitis ascribed to specific agent

Secondary SOC (Optional)

Skin and subcutaneous tissue disorders

Justification statement is required

Justification 


Please consider including the gradation of chemical burns similar to the gradation of thermal burns under HLT Thermal burns to assist with coding and analysis.

Attach supporting document (Optional)

Attachment
000681 C:\Users\is804733\Desktop\SupportingInforma Browse...

- Sample entry for a new PT in WebCR
- Justification and supporting documentation is important to help MSSO understand the need

000681 33



Proactive MedDRA Maintenance

- What is the proactive approach?
 - Corrections/improvements made internally by the MSSO
 - General changes suggested by users
- Submitting ideas
 - Send to MSSO Help Desk. Justification is helpful.
 - Example: Review placement of bruise and contusion terms to facilitate coding and analysis
- Evaluation of proposals
 - Final disposition is not time limited; MSSO may take time to review
 - Proactive approach does not replace usual CR process

000681 34



MedDRA

MedDRA Version Analysis Tool (MVAT)

- Web-based (<https://tools.meddra.org/mvat>)
- Free to all users
- Features
 - Version Report Generator (produces exportable report comparing any two versions)
 - Data Impact Report (identifies changes to a specific set of MedDRA terms or codes uploaded to MVAT)
 - Search Term Change (identifies changes to a single MedDRA term or code)

000681

35




MedDRA

MedDRA Version Analysis Tool (MVAT) (cont)

- User interface and report output available in all MedDRA languages
- Ability to run reports on supplemental changes
- Option to run reports on secondary SOC changes

000681

36



MedDRA Version Analysis Tool (MVAAT)

Version Report Description

Select Different Versions to Compare

Language: English

Starting Version: MedDRA 24.1 English

Ending Version: MedDRA 25.0 English

Include Secondary SOC Information:

Select SOCs to filter (default is all SOCs):

- Blood and lymphatic system disorders
- Cardiac disorders
- Congenital, hereditary and genetic disorders
- Ear and labyrinth disorders
- Endocrine disorders
- Eye disorders
- Gastrointestinal disorders
- General disorders and administration site conditions
- Hepato-biliary disorders
- Injury system disorders
- Infections and infestations
- Neoplasms, benign and malignant, neoplasms of uncertain behavior

Note: The starting MedDRA version must be older than the ending MedDRA version


Run Version Report | As an MSSO employee, you could view site usage statistics

Preferred Language: English

Release/Supplemental View: Release

Menu: Home, Search Term Change, Data Impact Report, Logout

000681 37




MedDRA Desktop Browser (MDB)
Download MDB and release files from MedDRA website

MedDRA Web-Based Browser (WBB)
<https://tools.meddra.org/wbb/>



Mobile MedDRA Browser
<https://mmb.meddra.org>

000681 38




MSSO's MedDRA Browsers (cont)

- Features
 - Each require MedDRA ID and password
 - View/search MedDRA and SMQs
 - Support for all MedDRA languages
 - Language specific interface
 - Ability to export search results and Research Bin to local file system (MDB and WBB only)





000681 39



MDB and WBB Special Features

- Preview upcoming (supplemental) changes in next release*
 - *Supplemental view not available on MDB*
- View primary **and** secondary link information
- Upload terms to run against SMQs
- Advanced search options (e.g., NOT, OR)



000681 40



Data WBB Supplemental View

- Where will Change Requests I submitted appear in next release of MedDRA?
- What are the changes in an area of MedDRA in the next release?

Change View to Supplementals

000681

41



WBB Supplemental View (cont)

- Display changes color to pink
- Supplemental terms highlighted by broken green line
- Changes for the next release are displayed immediately after they are approved by the MSSO

MedDRA Browser - Supplemental View

Search Options

Select SOCs to Search (default is all SOCs)

Total Search Results: 16
Details: PT (1), LLT (15)

Search Results (Supplemental)

Term Details in Primary Language

LLT - Lowest Level Term


MedDRA Code	MedDRA Term	Change
10077122	Device delivery system issue	Y

LLT Occurrences in MedDRA (Supplemental)

- Device delivery system issue
 - Device issue NEC
 - Device issue
 - Product issues

000681

42



MedDRA

MedDRA Browser Demonstration and Instruction

000681

43

The slide features a MedDRA logo in the top left corner, consisting of a blue circle with vertical green and white stripes, followed by the text 'MedDRA'. The main title 'MedDRA Browser Demonstration and Instruction' is centered in a green font. In the bottom left corner, the number '000681' is displayed. In the bottom right corner, the number '43' is shown. The background includes a decorative graphic of several vertical bars of varying heights in shades of green and blue, located in the lower right quadrant.




MedDRA

Coding Exercises

000681

44

The slide features a MedDRA logo in the top left corner, consisting of a blue circle with vertical green and white stripes, followed by the text 'MedDRA'. The main title 'Coding Exercises' is centered in a green font. In the bottom left corner, the number '000681' is displayed. In the bottom right corner, the number '44' is shown. The background includes a decorative graphic of several vertical bars of varying heights in shades of green and blue, located in the lower right quadrant.




Assessing the Reported Information


- Consider what is being reported. Is it a:
 - Clinical condition - Diagnosis, sign or symptom?
 - Indication?
 - Test result?
 - Injury?
 - Procedure?
 - Medication error?
 - Product use issue?
 - Product quality issue?
 - Social circumstance?
 - Device issue?
 - Procedural complication?
- **Is it a combination of these?**

The type of report will influence the way you search for a suitable LLT. It may indicate in which SOC you expect to find the closest match.

000681 45



MedDRA Browsing Tips



HELPFUL TIPS

- First, try using reporter's actual words
- Be aware of MedDRA's specificity
- Exploit MedDRA's hierarchy – if an LLT is close to what you need, look at its "siblings" and "parent"
- Check where the LLT lies in MedDRA (i.e., check the hierarchy above to be sure it represents the verbatim term accurately)

000681 46



MedDRA Browsing Tips (cont)



- Use "top-down" and "bottom-up" navigation
- Use available resources for difficult verbatim terms (web search, medical dictionaries, colleagues)
- Use advanced Boolean search terms features (i.e., "begins with", "exact match", "ends with", "not contains", "and", "or") when needed
- Become familiar with MedDRA Concept Descriptions

000681

47




Concept Descriptions

- Descriptions of how a concept is interpreted, used, and classified in MedDRA
- **Not a definition**
- Intended to aid accurate and consistent use of MedDRA
- Overcome differences in medical practice worldwide
- Accessible in MSSO's browsers

000681

48



MedDRA Concept Descriptions (cont)

MedDRA Browser

Preferred Language: English | MedDRA Concept Descriptions | Legends | About | Search History | New Browser Window | MedDRA Documentation | User C

Language and Version Options: English | English | English | 19.1 | Browser View: SOC | Display O

Term: mssotools.com

MedDRA CONCEPT DESCRIPTIONS

This appendix provides a list of MedDRA concept descriptions. A concept description is a description of how a concept is interpreted, used, and classified within the MedDRA terminology and is not a definition. The concept descriptions are intended to aid the consistent and accurate use of MedDRA in coding, retrieval, and analysis and to overcome the differences of medicine practice worldwide. The MSSO expects this appendix to be a working document and grow as subscribers request additional concepts to be documented.

AB C D E F G H I J K L M N O P Q R S T U V W X Y Z

A


Abuse

For the purposes of term selection and analysis of MedDRA-coded data, abuse is the intentional, non-therapeutic use by a patient or consumer of a product – over-the counter or prescription – for a perceived reward or desired non-therapeutic effect including, but not limited to, "getting high"(euphoria). Abuse may occur with a single use, sporadic use or persistent use of the product.

Select SOCs to S

- Blood and lymphatic disorders
- Cardiac disorders
- Congenital, familial and hereditary disorders
- Ear and labyrinthine disorders
- Endocrine disorders
- Eye disorders
- Gastrointestinal disorders
- General disorders and symptoms
- Hepatobiliary disorders
- Immune system disorders
- Infections and infestations
- Injury, poisoning and procedural complications
- Investigations
- Metabolism and nutrition disorders
- Musculoskeletal and connective tissue disorders
- Neoplasms (benign, malignant, and unspecified)
- Nervous system disorders
- Pregnancy, puerperium and perinatal conditions
- Product issues
- Psychiatric disorders
- Renal and urinary disorders
- Reproductive system and breast disorders

000681 49



MedDRA Exercise 1

The patient states she has been experiencing headaches, dizziness and vertigo.

_____ LLT → _____ PT

_____ LLT → _____ PT

_____ LLT → _____ PT

000681 50



MedDRA

Exercise 2

Lab results indicate an increase in erythrocytes.

_____ LLT → _____ PT

000681



51



MedDRA

Exercise 3

Drug was contaminated with Staphylococcus.

_____ LLT → _____ PT

000681



52



MedDRA

Exercise 4

A six year old boy was admitted for toxicity after accidentally ingesting the remaining antihypertensive tablets in the bottle.

_____ LLT → _____ PT

_____ LLT → _____ PT

000681

53



MedDRA

Exercise 5

The patient's urinary catheter was blocked.

_____ LLT → _____ PT

000681


54



Coding with MedDRA


000681

55



What are Coding for Conventions?

- Written guides and sets of principles for using MedDRA that help achieve consistency in coding and data retrieval
- Conventions harmonize exchange of MedDRA coded data worldwide
- Common topics
 - Misspellings, abbreviations and acronyms
 - Combination terms and “due to” concepts
 - “Always query” terms, e.g., “Chest pain”



000681

56



MedDRA

Why Do We Need Coding Conventions?



- Differences in medical aptitude of coders
- Consistency concerns (many more “choices” in MedDRA vs. older terminologies)
- Even with autoencoder, may still need manual coding

000681

57



MedDRA

Autoencoder Pitfalls

- Inappropriate terms may be selected by autoencoder
- Review all autoencoding carefully
 - “Allergic to CAT scan” autoencoded as:
LLT *Allergic to cats*
 - “Myocardial infarction in the fall of 2000” autoencoded as:
LLT *Myocardial infarction*
LLT *Fall*

000681

58



MedDRA

Can I Make Coding Conventions Specific to My Company/Product?

- MedDRA may reduce the need to do this because:
 - Increased size/granularity results in more accurate representation of data
 - Secondary SOC allocations allow for different “views” of the data
- This type of approach should be done cautiously

000681

59



MedDRA

Synonym Lists

- Recurring verbatims – one-time assignment to an LLT
- Promotes consistency
- Increases likelihood of autoencoding “hit”
- Maintenance required

Verbatim	LLT	Comment
Throbbing above temple Aching all over head Pulsing pain in head	Headache	
Muscular pain in legs	Myalgia of lower extremities	LLT <i>Myalgia of lower extremities</i> is a better choice than LLT <i>Muscular pain</i> since it captures both the event and body site

000681

60



Quality Assurance (QA) Reports

- Allows reviewers to check for consistency (both auto-encoded and human-coded terms)
- Check for adherence to/deviation from coding conventions
- Check for emerging drifts/biases
- Multiple data views (verbatimims to coded terms; coded term to verbatimims; by SOC, etc.)

000681

61



QA Sample Report

SOC	HLT	PT	Verbatim	Count
Respiratory, thoracic and mediastinal disorders				
	Bronchospasm and obstruction			
		Wheezing		
			WHEEZING	16
			Wheeze	5
			INCREASED WHEEZING	1
			Breathing suppressed wheezing	1
			HYPERREACTIVITY AND WHEEZING	1
			wheeze in chest	1
	Laryngeal and adjacent sites disorders NEC (excl infections and neopla			
		Vocal cord disorder		
			SPASMODIC DYSTONIA OF THE VOCAL CORDS	1
	Newborn respiratory disorders NEC			
		Transient tachypnoea of the newborn		
			Transient hazy vision	1
			Transient tachypnea, neonatal	1
			Tachypnea of the newborn, transient	1

000681

62



MedDRA

Unqualified Test Name Term List

- MSSO developed and maintains list of unqualified test name terms
 - These terms (e.g., PT *Blood glucose*) should never be reported as AEs
 - Intended for use in E2B test name field only
- List can be used to check data quality
 - Identifies inappropriate terms in data fields other than test name data element
 - Intended as recommendation only

000681

63




MedDRA

Unqualified Test Name Term List (cont)

- Link on Support Documentation page on MedDRA website
- Spreadsheet of LLT/PT names and codes from SOC *Investigations*
 - >4,200 terms in v25.0
- Explanatory document
 - Purpose, uses, development of list
- Also available in Japanese on JMO website


000681

64



MedDRA Term Selection: Points to Consider Document

000681 65



MedDRA Term Selection: Points to Consider (MTS:PTC)

**MedDRA® TERM SELECTION:
POINTS TO CONSIDER**
ICH-Endorsed Guide for MedDRA Users

Release 4.22

March 2022

Disclaimer and Copyright Notice

This document is protected by copyright and may, with the exception of the MedDRA and ICH logos, be used, reproduced, incorporated into other works, adapted, modified, translated or distributed under a public license provided that ICH's copyright in the document is acknowledged at all times. In case of any adaption, modification or translation of the document, reasonable steps must be taken to clearly label, demarcate or otherwise identify that changes were made to or based on the original document. Any impression that the adaption, modification or translation of the original document is endorsed or sponsored by the ICH must be avoided.

The document is provided "as is" without warranty of any kind. In no event shall the ICH or the authors of the original document be liable for any claim, damages or other liability arising from the use of the document.

The above-mentioned permissions do not apply to content supplied by third parties. Therefore, for documents where the copyright vests in a third party, permission for reproduction must be obtained from this copyright holder.

MedDRA® trademark is registered by ICH

- Provides term selection advice for industry and regulatory purposes
- Objective is to promote accurate and consistent term selection to facilitate common understanding of shared data
- Recommended to be used as basis for individual organization's own coding conventions

000681 66



MedDRA

MedDRA Term Selection: PTC (cont)

- Developed by a working group of the ICH Management Committee
- Updated annually in March
- Complete versions available in
 - English, Japanese, Chinese, Korean, Spanish, and Russian
- Condensed versions available for other MedDRA languages
- Available on MedDRA and JMO websites



000681

67



MedDRA

MTS:PTC Points of Note

- In some cases, with more than one option for selecting terms, a “preferred option” is identified but this does not limit MedDRA users to applying that option. Organizations should be consistent in their choice of option.
- Section 4.1 – Versioning (Appendix)
 - 4.1.1 Versioning methodologies
 - 4.1.2 Timing of version implementation

000681

68



MedDRA

PtC Documents

PtC Category	PtC Document	Purpose	Languages	Release Cycle
Term Selection	MedDRA Term Selection: Points to Consider	Promote accurate and consistent coding with MedDRA	English, Japanese, Chinese, Russian, Korean, and Spanish	Updated annually with the March release of MedDRA
	MedDRA Term Selection: Points to Consider Condensed Version	Shorter version focusing on general coding principles to promote accurate and consistent use of MedDRA worldwide	All MedDRA languages (except English, Japanese, and other languages with an available translation of the full MTS:PTC document)	Update as needed
Data Retrieval and Presentation	MedDRA Data Retrieval and Presentation: Points to Consider	Demonstrate how data retrieval options impact the accuracy and consistency of data output	English, Japanese, Chinese, Russian, Korean, and Spanish	Updated annually with the March release of MedDRA
	MedDRA Data Retrieval and Presentation: Points to Consider Condensed Version	Shorter version focusing on general retrieval and analysis principles to promote accurate and consistent use of MedDRA worldwide	All MedDRA languages (except English, Japanese, and other languages with an available translation of the full DRP:PTC document)	Update as needed

000681

69



MedDRA

PtC Documents (cont)

PtC Category	PtC Document	Purpose	Languages	Release Cycle
General	MedDRA Points to Consider Companion Document	More detailed information, examples, and guidance on specific topics of regulatory importance. Intended as a "living" document with updates based on users' needs. First edition covered data quality and medication errors. Updated in July 2020 (Release 1.1). Release 2.0 in October 2020 included a section on product quality issues.	English and Japanese	Updated as needed

000681

70



MedDRA

General Term Selection Principles

- Quality of Source Data
- Quality Assurance
- Do Not Alter MedDRA
- Always Select a Lowest Level Term
- Select Only Current Lowest Level Terms
- When to Request a Term
- Use of Medical Judgment in Term Selection
- Select Terms for All Reported Information, Do Not Add Information

000681

71



MedDRA

Quality of Source Data Quality Assurance

- Quality of original information impacts quality of output
- Obtain clarification of data
- Can be optimized by careful design of data collection forms and proper training of staff
- Organizations' coding guidelines should be consistent with MTS:PTC
- Review of term selection by qualified individuals
- Human oversight of automated coding results

000681

72



MedDRA

Do Not Alter MedDRA

- MedDRA is a standardized terminology with a pre-defined term hierarchy
- Users must not make *ad hoc* structural alterations, including changing the primary SOC allocation



If terms are incorrectly placed, submit a change request to the MSSO

000681

73



MedDRA

MTS:PTC General Principle




- Always Select a Lowest Level Term
Select Only Current LLTs

- ✓ Select the Lowest Level Term that most accurately reflects the reported verbatim information

"Abscess on face"

→ Do not simply select LLT *Abscess*

→ Select a term with greater specificity LLT *Facial abscess*



- ✓ Select current LLTs only
 - Non-current terms for legacy conversion/historical purposes

000681

74



MedDRA

When to Request a Term Use of Medical Judgment

- Avoid company-specific “work-arounds” for MedDRA deficiencies. If concept not adequately represented in MedDRA, submit Change Request to MSSO.
- If no exact match in MedDRA, use medical judgment to match to an existing term that adequately represents the concept

000681

75



MedDRA

Select Terms for All Reported Information

- Select terms for every AR/AE reported, regardless of causal association
- Select terms for device-related events, product quality issues, medication errors, medical and social history, investigations and indications as appropriate

000681

76



MedDRA

Do Not Add Information

- Do not make diagnosis if only signs/symptoms reported

Reported	LLT Selected	Comment
Abdominal pain, increased serum amylase, and increased serum lipase	Abdominal pain	It is inappropriate to assign an LLT for diagnosis of "pancreatitis"
	Serum amylase increased	
	Lipase increased	

000681

77



MedDRA

General Principles



- Selecting More Than One Term

- ✓ Can select more than one LLT to represent reported information.
 - Selecting one term may lead to loss of specificity
 - Selecting more than one term may lead to redundant counts



Document your procedures!


Report:
"Metastatic
gingival cancer"

Select LLT Gingival cancer **OR** LLT
Metastatic carcinoma

Select LLT Gingival cancer **AND** LLT
Metastatic carcinoma

000681

78




MedDRA Term Selection Points

Section 3

- Diagnoses and Provisional Diagnoses with or without Signs and Symptoms
- Death and Other Patient Outcomes
- Suicide and Self-Harm
- Conflicting/Ambiguous/Vague Information
- Combination Terms
- Age vs. Event Specificity
- Body Site vs. Event Specificity
- Location-Specific vs. Microorganism-Specific Infection
- Modification of Pre-existing Conditions
- Exposures During Pregnancy and Breast Feeding
- Congenital Terms
- Neoplasms
- Medical and Surgical Procedures
- Investigations

000681 79



MedDRA Term Selection Points

Section 3

- Medication Errors, Accidental Exposures and Occupational Exposures
- Misuse, Abuse and Addiction
- Transmission of Infectious Agent via Product
- Overdose, Toxicity and Poisoning
- Device-related Terms
- Drug Interactions
- No Adverse Effect and "Normal" Terms
- Unexpected Therapeutic Effect
- Modification of Effect
- Social Circumstances
- Medical and Social History
- Indication for Product Use
- Off Label Use
- Product Quality Issues

000681 80



MedDRA

Important Coding Errors

- Missed Concepts
 - All medical concepts described after the product is taken should be coded
 - Example: “*The patient took drug X and developed alopecia, increased LFTs and pancreatitis*”. Manufacturer only codes alopecia and increased LFTs (missed concept of pancreatitis)
 - Example: “*The patient took drug X and developed interstitial nephritis which later deteriorated into renal failure*”. Manufacturer only codes interstitial nephritis (missed renal failure concept)

000681

81



MedDRA

Important Coding Errors (cont)

- “Soft Coding”
 - Selecting a term which is both less specific and less severe than another MedDRA term is “soft coding”
 - Example: “*Liver failure*” coded as hepatotoxicity or increased LFTs
 - Example: “*Aplastic anemia*” coded as unspecified anemia
 - Example: “*Rash subsequently diagnosed as Stevens Johnson syndrome*” coded as rash

000681

82



MedDRA

Diagnoses and Provisional Diagnoses

SINGLE DIAGNOSIS	
DEFINITIVE DIAGNOSIS	PROVISIONAL DIAGNOSIS
Single diagnosis without signs and symptoms •Diagnosis (only possible option)	Single provisional diagnosis without signs and symptoms •Provisional diagnosis (only possible option)
Example: "Myocardial infarction" → select "Myocardial infarction"	Example: "Possible myocardial infarction" → select "Myocardial infarction" (select term as if definitive diagnosis)

000681



Similar principles apply for multiple diagnoses

83



MedDRA

Diagnoses and Provisional Diagnoses (cont)

SINGLE DIAGNOSIS	
DEFINITIVE DIAGNOSIS	PROVISIONAL DIAGNOSIS
Single diagnosis with signs/symptoms •Preferred: Diagnosis only	Single provisional diagnosis with signs/symptoms •Preferred: Provisional diagnosis and signs/symptoms
Example: "Anaphylactic reaction with rash, dyspnoea, hypotension, and laryngospasm" → select "Anaphylactic reaction"	Example: "Possible myocardial infarction with chest pain, dyspnoea, diaphoresis" → select "Myocardial infarction", "Chest pain", "Dyspnoea", and "Diaphoresis"

000681



Similar principles apply for multiple diagnoses

84



MedDRA

Diagnoses and Provisional Diagnoses (cont)

SINGLE DIAGNOSIS	
DEFINITIVE DIAGNOSIS	PROVISIONAL DIAGNOSIS
Single diagnosis with signs/symptoms •Alternate: Diagnosis and signs/symptoms	Single provisional diagnosis with signs/symptoms •Alternate: Signs/symptoms only (as provisional diagnosis may change)
Example: "Anaphylactic reaction with rash, dyspnoea, hypotension, and laryngospasm" → select "Anaphylactic reaction", "Rash", "Dyspnoea", "Hypotension", and "Laryngospasm"	Example: "Possible myocardial infarction with chest pain, dyspnoea, diaphoresis" → select "Chest pain", "Dyspnoea", and "Diaphoresis"

000681



Similar principles apply for multiple diagnoses

85



MedDRA

Diagnoses and Provisional Diagnoses (cont)

- Always include signs/symptoms not associated with diagnosis

Reported	LLT Selected
Myocardial infarction, chest pain, dyspnoea, diaphoresis, ECG changes and jaundice	Myocardial infarction Jaundice (note that jaundice is not typically associated with myocardial infarction)

000681

86



MedDRA

What Terms to Select?

- Sepsis leading to shock from possible spontaneous bacterial peritonitis or bowel perforation

Sepsis

Shock

Septic shock

Spontaneous bacterial peritonitis

Bowel perforation

000681

87



MedDRA

Conflicting/Ambiguous Information

- First, try to obtain more specific information

Reported	LLT Selected	Comment
Hyperkalaemia with a serum potassium of 1.6 mEq/L	Serum potassium abnormal	LLT <i>Serum potassium abnormal</i> covers both of the reported concepts (note: serum potassium of 1.6 mEq/L is a low result, not high)
GU pain	Pain	"GU" could be either "genito-urinary" or "gastric ulcer". If additional information is not available, then select a term to reflect the information that is known, i.e., LLT <i>Pain</i>

000681

88



MedDRA

Vague Information

- First, try to obtain more specific information

Reported	LLT Selected	Comment
Turned green	Unevaluable event	"Turned green" reported alone is vague; this could refer to a patient condition or even to a product (e.g., pills)
Patient had a medical problem of unclear type	Ill-defined disorder	Since it is known that there is some form of a medical disorder, LLT <i>Ill-defined disorder</i> can be selected

000681

89



MedDRA

What Terms to Select?

- Clinical complication of IUD

IUD complication (PT Complication associated with device)

Intra-uterine death (PT Foetal death)

Unevaluable event

- Hypoglycemia (blood glucose = 200 mg/dL)

Blood glucose abnormal

Blood glucose increased

Hypoglycemia

000681

90



MedDRA

Combination Terms

- One condition is more specific than the other

Reported	LLT Selected
Arrhythmia due to atrial fibrillation	Atrial fibrillation
Hepatic function disorder (acute hepatitis)	Hepatitis acute

- A MedDRA combination term is available

Reported	LLT Selected
Retinopathy due to diabetes	Diabetic retinopathy
Rash with itching	Itchy rash
Breast cancer (HER2 positive)	HER2 positive breast cancer

000681

91



MedDRA

Combination Terms (cont)

- If splitting provides more clinical information, select more than one term
- In all cases of combination terms, apply medical judgment

Reported	LLT Selected
Diarrhoea and vomiting	Diarrhoea Vomiting
Wrist fracture due to fall	Wrist fracture Fall
BRAF positive malignant melanoma	BRAF gene mutation Malignant melanoma

000681

92



MedDRA

What Terms to Select?

- Retinal disease from HIV with near total blindness (R and L)

Retinal damage

Retinal disorder

HIV disease

Blindness

HIV retinopathy

Blindness, both eyes

000681

93



MedDRA

Investigations

- Medical condition vs. investigation result

Reported	LLT Selected	Comment
Hypoglycaemia	Hypoglycaemia	LLT <i>Hypoglycaemia</i> links to SOC <i>Metabolism and nutrition disorders</i>
Decreased glucose	Glucose decreased	LLT <i>Glucose decreased</i> links to SOC <i>Investigations</i>

000681

94



MedDRA

Investigations (cont)

- Unambiguous investigation result

Reported	LLT Selected	Comment
Glucose 40 mg/dL	Glucose low	Glucose is clearly below the reference range

- Ambiguous investigation result

Reported	LLT Selected	Comment
His glucose was 40	Glucose abnormal	No units have been reported. Select LLT <i>Glucose abnormal</i> if clarification cannot be obtained.

000681

95



MedDRA

Investigations (cont)

- Investigation results consistent with diagnosis

Reported	LLT Selected	Comment
Elevated potassium, K 7.0 mmol/L, and hyperkalaemia	Hyperkalaemia	It is not necessary to select LLT <i>Potassium increased</i>

- Grouped investigation result terms

Reported	LLT Selected	Comment
Increased alkaline phosphatase, increased SGPT, increased SGOT and elevated LDH	Alkaline phosphatase increased SGPT increased SGOT increased LDH increased	Select four individual terms. A single term such as LLT <i>Liver function tests abnormal</i> should not be selected.

000681

96



MedDRA

What Terms to Select?

- Testing showed increased serum creatinine and BUN, with increased BUN/creatinine ratio

Increased serum creatinine

BUN increased

Blood urea nitrogen/creatinine ratio increased

Renal function tests NOS abnormal

- Patient had features of aldosterone excess

Aldosterone increased

Aldosteronism

Blood aldosterone abnormal

000681

97



MedDRA

Medication Errors

- See MedDRA Concept Descriptions
- Discussed in MedDRA Points to Consider Companion Document – Section 3



– Detailed examples

– “Questions and Answers” about medication errors

- “Top-down” navigation in HLGT *Medication errors and other product use errors and issues* is best approach for term selection

000681

98



MedDRA

Medication Errors (cont)

- Medication error with clinical consequences

Reported	LLT Selected	Comment
Patient was administered wrong drug and experienced hypotension	Wrong drug administered Hypotension	
Insulin was given using the wrong syringe resulting in the administration of an overdose. The patient developed hypoglycaemia.	Drug administered in wrong device Accidental overdose Hypoglycaemia	If an overdose is reported in the context of a medication error, the more specific term <i>LLT Accidental overdose</i> can be selected

000681

99



MedDRA

Medication Errors (cont)

- Medication error without clinical consequences

Reported	LLT Selected	Preferred Option
Medication was given intravenously instead of intramuscularly without any adverse effect	Intramuscular formulation administered by other route	✓
	Intramuscular formulation administered by other route No adverse effect	

000681

100



MedDRA

Medication Errors (cont)

- Important to record potential occurrence of medication error
- Unlikely to be reported as an adverse event but may need to be recorded in periodic safety reports

Reported	LLT Selected	Comment
Pharmacist notices that the names of two drugs look similar and is concerned that this may result in a medication error	Drug name look-alike Circumstance or information capable of leading to medication error	Note: this example is a potential medication error. LLT <i>Drug name look-alike</i> provides additional information about the nature of the potential medication error, and LLT <i>Circumstance or information capable of leading to medication error</i> indicates that there is a potential medication error.

000681

101



MedDRA

Overdose, Toxicity and Poisoning

If overdose, poisoning or toxicity is explicitly reported, select the appropriate term

- Overdose with clinical consequences

Reported	LLT Selected
Stomach upset from study drug Overdose	Stomach upset Overdose

- Overdose without clinical consequences

Reported	LLT Selected	Preferred Option
Patient received an overdose of medicine without any adverse consequences	Overdose	✓
	Overdose No adverse effect	

000681

102



MedDRA

What Term(s) to Select?

- The patient's renal function was measured every six months instead of on the monthly schedule recommended in the label for the drug
 - Medication monitoring error
 - Renal function test abnormal
 - Drug monitoring procedure incorrectly performed
- Unintentionally took more than maximum recommended dose due to dispensing error
 - Accidental overdose
 - Incorrect dose administered
 - Drug dispensing error

000681

103



MedDRA

Death and Other Patient Outcomes

- Death, disability and hospitalization are considered outcomes and not usually coded as adverse events (AE) or adverse reactions (AR)
- If one of these outcomes is the only reported information, select an appropriate LLT for coding
- If a death term in MedDRA adds important clinical information, code it along with reported ARs/AEs

Reported	LLT Selected
Patient experienced a rash and had sudden cardiac death	Rash Sudden cardiac death

000681

104



MedDRA

Drug Interactions

- Term includes reactions between drugs (including biologic products) and other drugs, foods, devices and alcohol
- If reporter states an interaction, select terms for interaction term and reported medical event(s)

Reported	LLT Selected
Patient drank cranberry juice which interacted with anticoagulant drug causing an INR increase	Food interaction INR increased

- If reporter does not specifically state an interaction, select terms for reported medical event(s) only

000681

105



MedDRA

Suicide and Self-Harm

- Coding of suicide attempts, completed suicides and self-harm should be accurate and consistent
- Do not assume that an overdose, even if intentional, is a suicide attempt
- If a self-harm report does not mention suicide or suicide attempt, only code self-injury term
- If a suicide attempt is fatal, select a term that reflects the outcome instead of the attempt

Reported	LLT Selected	Comment
Suicide attempt resulted in death	Completed suicide	Report death as an outcome

000681

106



MedDRA

What Term to Select?

- Death from cerebral hemorrhage

Sudden death

Death

Cerebral hemorrhage

Brain death

000681

107



MedDRA

What Term to Select?

- Patient was found dead

Death from natural causes

Death

Died in sleep

Found dead

000681

108



MedDRA

What Term(s) to Select?

- After taking an antihistamine along with her prescription proton pump inhibitor, a 53-year-old woman developed vertigo

Drug interaction NOS

Vertigo subjective

Vertigo

Drug interaction

000681

109



MedDRA

What Term(s) to Select?

- Deliberately took an overdose

Intentional overdose

Suicide attempt

Deliberate overdose

Overdose NOS

000681

110



MedDRA Misuse, Abuse and Addiction

Concept	Intentional?	By Whom?	Therapeutic Use?	Additional Sections in this Document
Misuse	Yes	Patient/consumer	Yes*	3.16.1
Abuse	Yes	Patient/consumer	No	3.16.2
Addiction	Yes	Patient/consumer	No	3.16.3
Medication error	No	Patient/consumer or healthcare provider	Yes	3.15
Off label use	Yes	Healthcare provider	Yes	3.27

* Definitions of misuse may not always include the concept of therapeutic use; misuse may be similar to the concept of abuse in some regions.

000681

111



MedDRA Coding Exercises

- Narratives and short verbatims
- Assess the reported terms
 - Identify what concepts are reported (diagnosis, death, investigations, etc.)
- Refer to the appropriate sections of the MTS:PTC for guidance on term selection
 - For example, Section 3.2 for death terms
- Use MTS:PTC preferred options (forget your organization's conventions)
- Use browser to search for and select LLTs

000681

112



MedDRA

Specific Tips for Narrative Exercises

- Overall, coding principles are the same as for short verbatim exercises
- Code all of the following:
 - Events (including procedures and investigations as needed)
 - Indications
 - Medical history
 - Social history

000681

113



MedDRA

Sample Narrative

A 75-year-old male receiving Drug X for rheumatoid arthritis developed an area of darkened skin on his chest. The patient's medical history is significant for peripheral vascular disease and cigarette smoking. The skin lesion was excised; it was revealed to be a seborrhoeic wart.

000681

114



MedDRA

Course Summary

- ✓ Described MedDRA's background, scope, and structure (including primary SOC allocation rules)
- ✓ Discussed maintenance of MedDRA, coding conventions, synonym lists, and coding QA
- ✓ Introduced the MedDRA Term Selection: Points to Consider document
- ✓ Discussed and presented examples of coding exercises with MedDRA

000681

115



MedDRA

MSSO Contacts

- Website
 - www.meddra.org
- Email
 - mssohelp@meddra.org
- Frequently Asked Questions
 - www.meddra.org/faq
- MedDRA Browsers
 - <https://www.meddra.org/meddra-desktop-browsers> (Desktop Browser)
 - <https://tools.meddra.org/wbb/> (Web-Based Browser)
 - <https://mmb.meddra.org> (Mobile Browser)

000681

116




MedDRA

MSSO Contacts (cont)


- Change Request Submission
 - <https://www.meddra.org/how-to-use/change-requests>
- Training Schedule
 - <https://www.meddra.org/training/schedule>
- MedDRA Support Documentation
 - <https://www.meddra.org/how-to-use/support-documentation>

000681 117



MedDRA

Thank You!



000681 118



Question and Answer Session

000681

119